



TRATAMIENTOS DIRIGIDOS A DIANAS

Dra. Virginia Calvo de Juan

H. U. Puerta de Hierro Majadahonda, Madrid








- Advisory board: Roche, AstraZeneca, MSD, BMS, Takeda, Sanofi, AMGEN
- Speaking: Roche, AstraZeneca, MSD, BMS, Takeda, Pfizer, Janssen




• EGFR (Ex19del, L858R)

- OA03.03: Aumolertinib plus anlotinib in advanced NSCLC with brain metastasis: a single-arm, phase II study
- PL03.13: FLAURA 2: Osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC
- MA13.06: Amivantamab, Lazertinib plus platinum-based chemotherapy in EGFR-mutated advanced NSCLC: Updated results from CHRYSALIS-2
- OA05.03: Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFRTKI and platinum-based chemotherapy: HERTHENA-Lung01
- MA13.03: BBT-176, a 4th generation EGFR TKI, for progressed NSCLC after EGFR TKI therapy: updated report from a phase 1 study
- MA04.04: A novel anti-EGFR/CD3 bispecific antibody exhibits potent efficacy for Osimertinib-resistant NSCLC




Pasi Janne, et al.










Baseline characteristics

· Patient demographics / clinical characteristics were balanced between arms, and almost half of patients had CNS metastases at baseline

Characteristics, %*	Osimertinib + platinum-pemetrexed (n = 279) [†]	Osimertinib monotherapy (n = 278) [†]
Sex: male / female	38 / 62	39 / 61
Age: median (range), years	61 (26–83)	62 (30–85)
Race: Chinese Asian / non-Chinese Asian / non-Asian	25 / 39 / 35	25 / 38 / 36
WHO PS: 0 / 1 [‡]	37 / 62	37 / 63
Smoking status: never / current / former	67 / 1 / 31	65 / 1 / 33
Histology: adenocarcinoma / adenosquamous / other	99 / 1 / 1	99 / 0 / 1
EGFR mutation at randomization§: Ex19del / L858R	61 / 38	60 / 38
Locally advanced / metastatic	5 / 95	3 / 97
CNS metastases	42	40
Extra-thoracic visceral metastases	53	54
Baseline tumor size, mean (SD) / median (range), mm	65 (42) / 57 (10–284)	64 (39) / 57 (11–221)




Iniciativa científica de:

Ge


lung cance research

PFS* by EGFR mutation type at baseline



Pasi Janne, et al.

Iniciativa científica de:





Common adverse events (≥15% of patients)*

	Osimertinib + platinu	Im-pemetrexed (n = 276)	Osir	nertinib mon	otherapy (n = 275)	
Anemia [†]	19.9	26.5	7.7 0.4			
Diarrhea	2.9 40.6				40.4 0.4	
Nausea	1.4 41.6		10.2 0			
Decreased appetite		27.9	8.7 0.7		ILD (grouped term) was reporte
Constipation		29.0	10.2 0		8 patients (3%) in 1	· ·
Rash		27.5	20.7	0	plus platinum-per	
Fatigue		9 24.6	9.1 0.4		10 patients (4%) in	
Vomiting	1	.1 25.3	6.2 0			
Stomatitis		0.4 24.3	17.8	0.4	monotherapy arm	(all grades)
Neutropenia [†]	4.3 18.8	18.1	7.6 1.5			
Paronychia		0.7 22.8		26.2 0.4		
COVID-19 [‡]		0.4 0.7 19.6	14.2 0			
ALT increase		1.4 18.8	7.3 0.4			
Thrombocytopenia [†]	2.2	11.6 17.8	9.1 1.1			
Dry skin		0 18.1		24.0 0		
AST increase		0.4 17.0	4.4 0.4			
Blood creatinine increase	Grade 1 / 2 Grade 3		4.4 0			
WBC count decrease	Grade 4	0.4 2.9 12.7	6.2 0.4		Grade 1 / 2 Grade 3	
Edema peripheral		0 15.2	4.4 0	_		
	60 40	20	Ō	20	40 6	0
		Patients wit	h adverse event	s, %		

• Of most common AEs (occurring in ≥15% of patients in either arm), all Grade 4 AEs in the osimertinib plus platinum-pemetrexed arm were hematological toxicities, known to be associated with chemotherapy; there were no common Grade 4 AEs in the monotherapy arm



Conclusions

- Osimertinib in combination with platinum-pemetrexed has demonstrated a statistically significant and clinically meaningful improvement in PFS over osimertinib monotherapy in patients with EGFRm advanced NSCLC (HR: 0.62 [95% CI 0.49, 0.79])
 - Median improvements in PFS were 8.8 and 9.5 months with combination vs monotherapy, per investigator and BICR, respectively (median 25.5 vs 16.7 and 29.4 vs 19.9 months per investigator and BICR, respectively)
- PFS benefits were consistent across all pre-defined subgroups
- · PFS2 and OS data were immature at this interim analysis
- The safety profiles were as expected for each treatment and were manageable with standard medical practice
- Further ongoing analyses include CNS response and progression, post-progression endpoints, subsequent therapies, and ctDNA analyses



Osimertinib plus platinum-pemetrexed offers a new first-line treatment option for patients with EGFRm advanced NSCLC

MA13.06: Amivantamab, Lazertinib plus platinum-based chemotherapy in EGFRmutated advanced NSCLC: Updated results from CHRYSALIS-2

n = 20

61 (38-76)

11 (55) 8 (40)

1 (5)

12 (60)

1 (1-3)

9 (45)

14 (70) 5 (25)

and OS



Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity¹⁻³

AEs (≥20%) by preferred term Associated with EGFR inhibit

- Lazertinib is a CNS-penetrant, 3rd-generation EGFR TKI with efficacy in activating EGFR mutations, T790M, and brain metastases4,5 Demographic and baseline
- The combination of targeted inhibition of EGFR/MET signaling with platinum-based chemotherapy could address the diverse and polyclonal resistance after progression on osimertinib

CHRYSALIS-2 (NCT04077463)						
	Dosing (21-day	cycle)				
Eligibility	Lazertinib	240 mg daily				
EGFR-mutated, advanced NSCLC post-TKI (max of	Amivantamab	1400/1750 ^b mg on C1 D1/D2, C1D8, C1D15, C2D1; 1750/2100 ^b mg C3+ Q3W				
3 prior lines)	Charactheren	Carboplatin (AUC5; stopped after 4 cycles)				
	Chemotherapy	Pemetrexed (500 mg/m ²) until disease progression				
		Duration of response • Progression-free survival Clinical benefit rate ^e • Overall survival				

Rash Paronychia Stomatitis


			Race			
			Asian			
			White			
			Black			
8, C1D1	5,		Exon 19 deletio	n / L85	8R	1
			ECOG PS 0 /1			4
4 cycles)			History of brain	metast	ases	
ease prog	ression		Median no. of p	rior line	s ^d (range)	
			Prior therapy ^d			
sion-free	e un di se l		1st/2nd-generat	tion EG	FR TKI	
survival	Survival		Osimertinib			
Survivar	/		Platinum-base	d chem	notherapy ^e	
<u>, n (%)</u>	Tot	al ^a	Grade ≥3			
ion					PFS	
	15 (1 (5)			
	12 (6 0)	0			
	12 (60)	0			
	8 (4	0)	2 (10)			
	6 (3	30)	1 (5)			
n						
	8 (4	0)	2 (10)			
	~ ('	, U)	2(10)			

disease characteristics, n (%)

Median age, years (range)

Female / male


ORR and Durability



Investigator-assessed response (n=20)					
ORR	50% (95% Cl, 27–73)				
Median DOR	Not estimable				
Ongoing response	8 of 10 responders				
DOR ≥6 months	8 of 10 responders				
CBR⁵	80% (95% Cl, 56–94)				

- At a median follow-up of 13.1 months, 11 (55%) patients remain on treatment
- 3 of 7 patients with SD as best response had SD duration ≥6 months, 2 of which remain on treatment
- A total of 5 patients were treated beyond investigatorassessed progression,^c with incremental median treatment duration after progression of 4.2 months (range, 3.1-7.1)

Paronychia	12 (60)	0								
Stomatitis	12 (60)	0								
Dermatitis acneiform	8 (40)	2 (10)								
Diarrhea	6 (30)	1 (5)				P	FS ^{a,b}			
Associated with MET inhibition							-			
Hypoalbuminemia	8 (40)	2 (10)	10	⁰⁰ – T			м		:14.0 mon	
Other					L			(9	5% Cl, 4.3–1	NE)
Neutropenia	18 (90)	14 (70)	s ree	80 -	<u>ک</u>	6 mont	าร			
IRR	13 (65)	0	L L		le le	70%		1 year		
Fatigue	10 (50)	5 (25)	progression-free				_	59%		
Nausea	10 (50)	0	ere o	60						
COVID-19	8 (40)	0	Lo lo							
Thrombocytopenia	8 (40)	5 (25)	S 4	40 -					L	
Constipation	7 (35)	0	4 Patients							
Decreased appetite	7 (35)	1 (5)		20 -						
Leukopenia	7 (35)	4 (20)	× -	20 -						
Alanine aminotransferase increased	6 (30)	0								
Anemia	6 (30)	2 (10)		0						
Pulmonary embolism	6 (30)	1 (5)		0	3	6	9	12	15	18
Aspartate aminotransferase increased	5 (25)	0				Month	s since fi	rst dose		
Back pain	5 (25)	0	No. at risk	20	16	13	10	7	2	0
Epistaxis	5 (25)	0	THE REPORT	2.0		15	10	'	-	0
Hemorrhoids	5 (25)	0								
Peripheral sensory neuropathy	5 (25)	0								



Se-Hoon Lee, et al.


MA13.06: Amivantamab, Lazertinib plus platinum-based chemotherapy in EGFRmutated advanced NSCLC: Updated results from CHRYSALIS-2



Treatment	 Amivantamab, lazertinib plus chemotherapy^a among <i>EGFR</i>-mutant NSCLC after TKI demonstrated: An ORR of 50% and median PFS of 14.0 months The median DOR and OS were not estimable, with 80% of patients alive at 1 year, suggesting immune-driven durability
benefits	
Safety	 No new safety signals were seen; the safety profile was consistent with that of the individual components Given the reduction in cytopenia events after completion of carboplatin therapy, additive cytotoxicity arising from carboplatin plus targeted therapies requires further investigation
C Key takeaway & next steps	 Combining amivantamab, lazertinib plus chemotherapy^a is promising and likely addresses the diverse and polyclonal resistance emerging after progression on osimertinib The safety and efficacy of this regimen is being evaluated in the phase 3, randomized, MARIPOSA-2 study (NCT04988295) in the post-osimertinib setting



OA05.03: Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFRTKI and platinum-based chemotherapy: HERTHENA-Lung01



Primary data cutoff, 21 Nov 2022^d

Snapshot data cutoff, 18 May 2023 (additional 6 months follow-up) Data are presented for the 5.6-mg/kg fixed-dose arm

- Efficacy from snapshot data cutoff-median study follow-up, 18.9 (range, 14.9-27.5) months
- Safety from primary data cutoff—median treatment duration, 5.5 (range, 0.7-18.2) months


HER3-DXd is an ADC composed of 3 parts1-4:

- A fully human anti-HER3 IgG1 mAb (patritumab)
- A topoisomerase I inhibitor payload (DXd)
- A tetrapeptide-based cleavable linker that covalently bonds the other 2 components

Iniciativa científica de:

research

GA



Helena Yu, et al.

OA05.03: Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFRTKI and platinum-based chemotherapy: HERTHENA-Lung01




Confirmed responses and survival		Prior EGFR TKI (any) and PBC (N=225)	Subset with prior 3G EGFR TKI and PBC (n=209)
cORR (95% CI), %	0	29.8 (23.9-36.2)	29.2 (23.1-35.9)
	CR	1 (0.4)	1 (0.5)
Best overall response (BICR), n (%)	PR	66 (29.3)	60 (28.7)
	SD ^a	99 (44.0)	91 (43.5)
	PD	43 (19.1)	41 (19.6)
	NE ^b	16 (7.1)	16 (7.7)
DCR (95% CI), %		73.8 (67.5-79.4)	72.7 (66.2-78.6)
DOR, median (95% CI), mo		6.4 (4.9-7.8)	6.4 (5.2-7.8)
PFS, median (95% CI), mo		5.5 (5.1-5.9)	5.5 (5.1-6.4)
OS, median (95%	CI), mo	11.9 (11.2-13.1)	11.9 (10.9-13.1)

Intracranial Responses (by CNS BICR) Observed With HER3-DXd


Intracranial Efficacy of HER3-DXd in Patients With Brain Metastases at Baseline

Intracranial response by CNS BICR per CNS RECIST	Patients with brain metastasis at baseline and no prior radiotherapy (N=30)ª
Confirmed ORR (95% CI), %	33.3 (17.3-52.8)
CR, n (%)	9 (30.0) ^b
PR, n (%)	1 (3.3)
SD, n (%) ^c	13 (43.3)
PD, n (%)	4 (13.3)
NE, n (%)	3 (10.0)
DCR (95% CI), %	76.7 (57.7-90.1)
DOR, median (95% CI), mo	8.4 (5.8-9.2)
Snapshot data cutoff, 18 May 2023. Median study follow-up, 18.9 (range, 14.9-27.5) months.	


Partial CNS Response in a Patient With a Measurable CNS BICR Target Lesion



Screening



Day 167



Snapshot data cutoff, 18 May 2023.

Median study follow-up, 18.9 (range, 14.9-27.5) months.

Any hematologic toxicities typically occurred early in treatment, were transient, and were not associated with clinical sequelae

OA05.03: Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFRTKI and platinum-based chemotherapy: HERTHENA-Lung01

 HER3-DXd provided clinically meaningful and durable efficacy (cORR, 29.8%) in patients with advanced EGFRmutated NSCLC that progressed following EGFR TKI and platinum-based chemotherapy; efficacy was observed across diverse mechanisms of EGFR TKI resistance and across a broad range of pretreatment tumor HER3 membrane expression Iniciativa científica de

- HER3-DXd showed clinically meaningful intracranial antitumor activity in patients with untreated brain metastases
 - Intracranial cORR, 33.3%
 - Intracranial DCR, 76.7%
- The safety profile of HER3-DXd in this population of heavily pretreated patients was manageable and tolerable and was consistent with previous reports
 - TEAE associated with treatment discontinuation, 7.1%
 - Adjudicated treatment-related ILD, 5.3%
- HER3-DXd has emerged as a promising therapy for patients with EGFR-mutated NSCLC after the failure of EGFR TKI and platinum-based chemotherapy, for whom available treatment options provide only limited efficacy

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Helena A. Yu, MD¹ 💿; Yasushi Goto, MD² 🕞; Hidetoshi Hayashi, MD, PhD³ 🌀; Enriqueta Felip, MD, PhD⁴ 🍥; James Chih-Hsin Yang, MD, PhD⁵ 💿;

Helena Yu, et al.




• EGFR (uncommon mutations)

- MA13.04: Final overall survival analysis of osimertinib for patients with NSCLC harboring uncommon EGFR mutations (KCSG-LU15-09)
- MA13.11: Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: a single-arm, phase II multi-center trial

MA13.04: Final overall survival analysis of osimertinib for patients with NSCLC harboring uncommon EGFR mutations (KCSG-LU15-09)





Final Overall Survival Analysis					
Clinical response	Osimertinib (n=35)	1.0-			
Objective response rate (95% CI)	51% (34, 68)	0.8-			
Disease control rate (95% CI)	89% (78, 99)				
Median progression-free survival, months (95% Cl)	8.0 (5.7, 10.3)	0.6-			
Median overall survival, months (95% CI)	27.0 (19.3, 34.7)	0.4-			
Median duration of response, months (95% CI)	13.0 (9.1, 16.9)				
Median progression-free survival 2, months (95% Cl)	16.0 (8.5, 23.5)	0.2-			
•Median follow-up duration: 61.0 months		0.0-			



Conclusions


 Osimertinib continued to show favorable activity after long-term follow-up in patients with NSCLC harboring uncommon EGFR mutations

- Median OS 27.0m (95%CI, 18.5-33.5), Median DOR 13.5m (range 1.0-43.0)

 Osimertinib had manageable safety profile, consistent with previous reports; no new safety signals were identified

Jang Ho Cho, et al.

MA13.11: Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: a single-arm, phase II multi-center trial




Uncommon EGFR mutation is defined as point mutation or duplication in exon 18-21 other than EGFR del19, L858R, T790M and exon 20 insertion.

List of uncommon EGFR mutations eligible for the study:

G719X, S768I, L861Q, G719X + S768I, G719X + L861Q, L861Q + S768I, L747S, S720A, E709A, exon 18 deletion

Primary endpoint: Objective response rate (H0: 20%, H1: 40%)

Secondary endpoint: PFS, OS, safety profile, resistance mechanisms based on the liquid NGS test



Туре	N(%)	Best response	N(%)	ORR
		Complete response	-	
G719X	13	Partial response	7(53.85)	53.8%
0/19/	(38.24)	Stable disease	6(46.15)	35.6%
	1	Progressive disease	-	
		Complete response		
S768I	1	Partial response	1(100.00)	100%
5/081	(2.94)	Stable disease	-	100%
	(Progressive disease	-	T
		Complete response	-	
	11	Partial response	6(54.55)	T
L861Q	(32.35)	Stable disease	3(27.27)	54.6%
		Progressive disease	-	T
		NA	2(18.18)	1
		Complete response		
G719X +	3	Partial response	1(33.33)	T
	-	Stable disease		33.3%
S768I	(8.82)	Progressive disease		1
		NA	2(66.67)	1
		Complete response		
Exon18	5	Partial response		0%
del	(14.71)	Stable disease	4(80.00)	0%
	(Progressive disease	1(20.00)	1
		Complete response		
Exon 19	1	Partial response		0%
ins	(2.94)	Stable disease	1(100.00)	0%
	()	Progressive disease		

SAFETY PROFILE

Patients with dose	N (%)
modification	
Temporally dose interruption	9 (26.5)
Dose reduction to 160mg	12 (35.3)
Permanent discontinuation	1 (2.9)

• Reason for permanent discontinuation: Gr 2 pneumonitis

Reasons for dose reduction include following Gr 1 or 2 AEs:

Iniciativa científica de:

research

5

Peripheral neuropathy, Fatigue, Mucosal inflammation, Myalgia, Bone pain, Paronychia, Dermatitis, Muscle spasm, Paresthesia, Asthenia, Decreased appetite, Headache, Insomnia, Nausea, Rash, Skin laceration

CONCLUSIONS

- This study includes the preliminary results of 34 patients (out of 36 patients) with uncommon EGFR mutation who were treated with 240mg Lazertinib as 1st line. Median follow-up duration 6.83 months (95% CI 4.76 – 8.08)
- The objective response rate was 44.1%, the disease control rate was 85.3%, and median PFS was 7.69 months (95% CI 4.44-NA) G719X (n = 13): ORR 53.8% L861Q (n = 11): ORR 54.6%
- The safety profile of Lazertinib in the study population was similar to previous reports.
- 42.4% of baseline liquid biopsy detects the same uncommon EGFR mutation that has been detected with other methods used for screening tests.
- The final analysis including the resistance mechanism will be presented in the future




• EGFR Exon 20 insertions

OA03.04: A phase 1b study of furmonertinib, an oral, brain penetrant, selective
 EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions



OA03.04: FAVOUR: A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions

5



Endpoints

Primary: ORR by IRC assessment; Secondary: DCR, DoR, PFS, OS, Depth of response, safety, quality of life

Most Frequent TRAEs (Incidence $\geq 20\%$)


Preferred Term, Number of Patient(s) (%)		Treatment-naive 240 mg (N = 30)		Previously Treated 240 mg (N = 28)		Previously Treated 160 mg (N = 28)	
	Total	Grade≥3	Total	Grade≥3	Total	Grade≥3	
Diarrhea	22 (73%)	0	24 (86%)	0	9 (32%)	2 (7%)	
Anemia	13 (43%)	0	7 (25%)	1 (4%)	4 (14%)	1 (4%)	
Aspartate aminotransferase increased	8 (27%)	0	7 (25%)	0	10 (36%)	0	
Alanine aminotransferase increased	7 (23%)	0	7 (25%)	1 (4%)	8 (29%)	0	
Blood creatinine increased	6 (20%)	0	8 (29%)	0	7 (25%)	0	
Mouth ulceration	9 (30%)	1 (3%)	4 (14%)	0	5 (18%)	0	
Rash	7 (23%)	0	6 (21%)	0	4 (14%)	0	
Electrocardiogram QT prolonged	8 (27%)	1 (3%)	4 (14%)	2 (7%)	2(7%)	0	
White blood cell count decreased	6 (20%)	1 (3%)	5 (18%)	0	6(21%)	0	
Decreased appetite	3 (10%)	0	8 (29%)	0	0	0	
Weight decreased	3 (10%)	0	7 (25%)	1 (4%)	3 (11%)	0	
Skin fissures	6 (20%)	0	3 (11%)	0	0	0	
Paronychia	6 (20%)	0	2 (7%)	0	1 (4%)	0	

Safety profile was consistent with the 80mg dose approved in China for classical EGFR mutations

Confirmed ORR by IRC by Cohort

Efficacy by IRC	Treatment Naïve 240mg N=28*	Previously Treated 240mg N= 26 [#]	Previously Treated 160mg N= 26 [#]
Confirmed ORR, % (95% CI)	78.6% 59.05%, 91.70%)	46.2% 26.59%, 66.63%)	38.5% (2).23%, 59.43%)
Best Response, n (%)		\bigcirc	
Partial response (PR)	22 (78.6%)	12 (46.2%)	10 (38.5%)
Stable disease (SD)	6 (21.4%)	12 (46.2%)	12 (46.2%)
Progressive disease (PD)	0	0	4 (15.4%)
Not evaluable/Not done	0 / 0	1 (3.8%) / 1 (3.8%)	0 / 0
DoR, median (months) (95% CI)	15.2 (8.74, 24.84)	13.1 (5.62, 13.80)	9.7 (5.59, NA)
DCR (CR+PR+SD), % (95% CI)	100.0% (87.66%, 100.00%)	92.3% (74.87%, 99.05%)	84.6% (65.13%, 95.64%)

Depth of Response by Cohort and EGFR Exon20ins Mutation Subtype



- Promising efficacy in both treatment naïve and previously treated patients
- Well-tolerated safety profile: the most common TRAE observed at the 240mg dose was low-grade diarrhea
- Phase III study in first-line patients (FURVENT/FURMO-004; NCT05607550)

Baohui Han, et al.

Gecp


lung cance research



• ALK

- OA03.05: A randomized, phase 3 study of iruplinalkib (WX-0593) vs crizotinib in locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC)
- MA06.11: Lorlatinib for previously treated ALK-positive advanced NSCLC: updated efficacy and safety data from a phase 2 study in China

OA03.05: A randomized, phase 3 study of iruplinalkib (WX-0593) vs crizotinib in ALK TKI-naïve, locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC): INSPIRE



Conclusions


- Iruplinalkib demonstrated significantly improved progression-free survival (PFS) vs crizotinib in this preplanned interim
 analysis
 - median PFS 27.70 vs 14.62 months; hazard ratio (HR)=0.344
- Iruplinalkib showed high objective response rate (ORR) (93.0%) and responses were durable (median DoR 26.78 months)
- · Iruplinalkib showed improved central nervous system (CNS) efficacy vs crizotinib
 - Intracranial ORR 90.9% vs 60.0%
 - > Intracranial response was durable with iruplinalkib (median intracranial DoR 20.14 vs 9.26 months)
- · Iruplinalkib was well tolerated without new safety signals
- Iruplinalkib may be a new treatment option for patients with advanced ALK-positive and ALK TKI-naïve non-small cell lung cancer (NSCLC)

IRC-assessed objective response

IRC-assessed objective response rate (ITT Population)

	lruplinalkib (N=143)	Crizotinib (N=149)
Objective response, n (%)		
PR	133 (93.0)	133 (89.3)
ORR, n (%)	133 (93.0)	133 (89.3)
95% CI	87.5-96.6	83.1-93.7
Difference in ORR, %	3.7 (P=	0.2694)
SD*, n (%)	5 (3.5)	9 (6.0)
Time to objective response, months, median (range)	1.84 (0.5-11.1)	1.84 (0.9-9.1






Iniciativa científica de:

lung cance research

Primary Endpoint: IRC-Assessed PFS (ITT)



Iruplinalkib approved in China (June 2023) for Tx of *ALK*-positive, crizotinib resistant or intolerable advanced NSCLC

Runxiang Yang, et al.





• ROS-1

OA03.06: Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC:
 Update from the pivotal phase 1/2 TRIDENT-1 trial



OA03.06: Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC: Update from the pivotal phase 1/2 TRIDENT-1 trial






Of patients in the ROS1 TKI-naïve cohort treated at the RP2D (n = 63), cORR was 78% (95% CI, 66-87) and median DOR was NE (95% CI, 25.6-NE)^s

	TKI-naïve (N = 71)	1 TKI and no chemo (N = 56)
ORR	79%	38%
CR	10%	5%
PR	69%	32%
SD	15%	41%
mPFS	35 .7 months	9 months
Intracranial ORR	89%	38%

Iniciativa científica de:


lung cance research






OA03.06: Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC: Update from the pivotal phase 1/2 TRIDENT-1 trial







 Of patients in the 1 prior ROS1 TKI and no prior chemo cohort treated at the RP2D (n = 53), median PFS was 9.0 months (95% CI, 6.8-19.6)^e and median OS was 20.5 months (95% CI, 17.8-NE)^f

Conclusions

- In TRIDENT-1, with a median follow-up of over 20 months, repotrectinib continued to demonstrate durable clinical activity in patients with *ROS1*+ NSCLC
- In TKI-naïve patients, median DOR and PFS (95% CI) were 34.1 (25.6-NE) months and 35.7 (27.4-NE) months, respectively; no patient developed an emergent *ROS1* resistance mutation at disease progression
- Clinically meaningful activity was also seen in TKI-pretreated patients, including in the presence of solvent front mutation
- Repotrectinib led to durable intracranial responses, and may have delayed or prevented the development
 of brain lesions in patients without baseline brain metastases
- Repotrectinib safety in patients treated at the RP2D was manageable and consistent with previous reports in all treated patients
- These results from TRIDENT-1 demonstrate repotrectinib as a potential new standard of care option for TKI-naïve and TKI-pretreated patients with ROS1+ locally advanced or metastatic NSCLC

Byoung Chul Cho, et al.




• KRAS G12C


- MA06.04: KRYSTAL-1: Two-year follow-up of adagrasib (MRTX849) monotherapy in patients with advanced/metastatic KRASG12C-mutated NSCLC
- MA06.05: CodeBreak 101: Safety and efficacy of sotorasib with carboplatin and pemetrexed in KRAS G12C-mutated advanced NSCLC

MA06.04: KRYSTAL-1: Two-year follow-up of adagrasib (MRTX849) monotherapy in patients with advanced/metastatic KRASG12C-mutated NSCLC






Treatment-Related Adverse Events and Long-Term Safety




- ≥1 TRAE occurred in 128/132 (97%) patients
- 0/12 (0%) patients⁴ who received KO <30 days before adagrasib had Grade ≥3 = hepatotoxicity^e
- One patient discontinued treatment due to Grade 3 hepatotoxicity

TRAEs With New Onset >1 Year (N=43)



- 43/132 patients (32.6%) received adagrasib for >1 year
- 29 of these 43 patients (67%) had a new onset TRAE after >1 year New onset Grade ≥2 GLTRAEs occurred in 1 patient (2%; Grade 2 diarrhea); no
- New onset Grade ≥ 2 Grade ≥ 2 for treats occurred in a patient (2%, Grade 2 dialinea), no patients had Grade ≥ 2 hepatotoxicity with onset >1 year

Efficacy Outcomes at Two-Years



Objective responses were observed in 43% of patients (55/128); DCR was 80%

Median DOR was 12.4 months (95% Cl, 7.0–15.1)*

Conclusions and Future Directions

- In this pooled analysis of patients with previously treated KRAS^{G12C}-mutated NSCLC, adagrasib demonstrated durable efficacy, with a median OS of 14.1 months and 2-year OS rate of 31%
- Exploratory analyses suggested durable clinical benefit in patients with treated, stable CNS metastases at baseline (median OS of 14.7 months), with clinical benefit noted across most baseline co-mutations
- Adagrasib had a manageable long-term safety profile; most TRAEs with onset >1 year were of low grade and included fewer GI TRAEs
- Treatment management by dose modification did not lead to a decrease in OS (2-year OS rate of 32%)
- Adagrasib was associated with a low rate of Grade ≥3 hepatotoxicity and was not observed in any patients who
 received adagrasib within 30 days of prior IO
- A confirmatory Phase 3 study is evaluating adagrasib vs docetaxel in previously treated patients with KRAS^{G12C}-mutated NSCLC, in North America, Europe, Asia, and Australia (KRYSTAL-12; NCT04685135)

MA06.05: CodeBreak 101: Safety and efficacy of sotorasib with carboplatin and pemetrexed in KRAS G12C-mutated advanced NSCLC



58%


≥ 5% of all patients

Patients %

21%

16%

32%



Efficacy

	Sotorasib + Carboplatin + Pemetrexed		100 First-line (n = 20)) Second-line (n	Second-line (n = 13)		
Response by Investigator Assessments*	First-line (n = 20)	Second-line (n = 13)	90 - 80 -	62%	75% (n = 3/4) 67%	67%		
ORR, n (%)	13 (65) [†]	7 (54)	70	(n = 8/13)	(n = 2/3			
Best overall response, n (%)			* 60	50% (n = 2/4)		50% (n = 3/6)		
Complete response	0	1 (8)	8 50 AD					
Partial response	13 (65)	6 (46)						
Stable disease	7 (35)	4 (31)	30 -					
Progressive disease	0	1 (8)	20					
Not evaluable / not done	0	1 (8)	10					
DCR (95% CI)	20 (100) (83.2, 100)	11 (85) (54.6, 98.1)	0	< 1%	1–49% PD-L1 Expressio	≥ 50%		

ORR was 65% in the first-line setting and 54% in the second-line setting

ORR was similar across PD-L1 expression levels

Conclusions

- Sotorasib in combination with pemetrexed and carboplatin showed promising clinical activity in KRAS G12C-mutated advanced NSCLC among patients treated in the first- and second-line settings
- Common TRAEs were consistent with sotorasib and platinum doublet-based regimens^{3,4}
- ORR was 65% and 54% in the first- and second-line settings, respectively
- DCR was 100% and 85% in the first- and second-line settings, respectively
- Longer follow-up is ongoing to assess the durability of this combination
- Sotorasib with pemetrexed and carboplatin versus pembrolizumab with pemetrexed and carboplatin is being evaluated in the first-line setting in patients with KRAS G12C-mutated advanced NSCLC. negative for PD-L1 (Phase 3 CodeBreaK 202 trial; NCT05920356)



Jeffrey Clarke, et al.



• HER-2

 MA13.11: Trastuzumab Deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer: primary results of DESTINY-Lung02


• HER-2 Exon 20 Insertion

 MA13.09: Efficacy and safety of poziotinib in HER2 Exon 20 Insertion NSCLC patients who received at least 2 previous systemic therapies


MA13.11: Trastuzumab Deruxtecan in patients with HER2-mutant metastatic nonsmall cell lung cancer: primary results of DESTINY-Lung02


DESTINY-Lung02

Blinded, randomized, multicenter, international, noncomparative, phase 2 trial (NCT04644237)



Efficacy summary	N = 102	N = 50
Confirmed ORR, ^a n (%) [95% Cl]	50 (49.0) [39.0-59.1]	28 (56.0) [41.3-70.0]
CR PR SD PD Non-evaluable ^b	1 (1.0) 49 (48.0) 45 (44.1) 4 (3.9) 3 (2.9)	2 (4.0) 26 (52.0) 18 (36.0) 2 (4.0) 2 (4.0)
DCR,° n (%) [95% Cl]	95 (93.1) [86.4-97.2]	46 (92.0) [80.8-97.8]
Median DoR, de months (95% CI)	16.8 (6.4-NE)	NE (8.3-NE)
Median TTIR, ^d months (range)	1.8 (1.2-7.0)	1.6 (1.2-11.2)
Median follow-up, months (range)	11.5 (1.1-20.6)	11.8 (0.6-21.0)






Iniciativa científica de:

Ge

lung cance

MA13.11: Trastuzumab Deruxtecan in patients with HER2-mutant metastatic nonsmall cell lung cancer: primary results of DESTINY-Lung02



- Median treatment duration was 7.7 months (range, 0.7-20.8) with T-DXd 5.4 mg/kg and 8.3 months (range, 0.7-20.3) with T-DXd 6.4 mg/kg
- The most common any-grade TEAEs in the T-DXd 5.4 mg/kg and 6.4 mg/kg arms included nausea (67.3% and 82.0%), neutropenia (42.6% and 56.0%), and fatigue (44.6% and 50.0%)
- The most common grade ≥3 TEAEs in the T-DXd 5.4 mg/kg and 6.4 mg/kg arms included neutropenia (18.8% and 36.0%) and anemia • (10.9% and 16.0%)

Conclusions

- T-DXd demonstrated deep and durable responses at both the 5.4 mg/kg and 6.4 mg/kg dose
 - The lower limit of the ORR 95% CI of both doses exceeded the benchmark of 26.4%
 - Responses were consistent regardless of HER2 mutation type, HER2 amplification status, and prior systemic anticancer therapy
- The safety profile was acceptable and generally manageable at both doses and favored the • 5.4 mg/kg dose
 - The observed safety profile was consistent with previous studies and no new safety signals were observed
 - Lower incidence of drug-related grade ≥3 TEAEs, serious TEAEs, and TEAEs associated with study drug discontinuations, dose reductions, and drug interruptions were observed with the 5.4 mg/kg dose
 - Adjudicated drug-related ILD rate was lower in the T-DXd 5.4 mg/kg arm than in the 6.4 mg/kg arm

Primary analysis results of DESTINY-Lung02 support the use of T-DXd 5.4 mg/kg for patients with previously treated HER2m NSCLC and reinforce T-DXd as the standard of care in this population

Journal of Clinical Oncology[®]

0

0

5



Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase 2 DESTINY-Lung02 Trial ascopubs.org/doi/full/10.1200/JCO.23.01361

Iniciativa científica de:

ing cance

research

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Koichi Goto, MD, PhD¹ (); Yasushi Goto, MD, PhD² (); Toshio Kubo, MD, PhD³; Kiichiro Ninomiya, MD, PhD⁴ (); Sang-We Kim, MD, PhD⁵;




Pasi Jänne, et al.

MA13.09: Efficacy and safety of poziotinib in HER2 Exon 20 Insertion NSCLC patients who received at least 2 previous systemic therapies

Gecp Iung cancer research


Poziotinib for HER2 exon20 insertion NSCLC in ZENITH20 trial



Clinical efficacy

In this heavily pre-treated population, the ORR was 30% DCR 71% PFS 5.5 months, similar to entire cohort 2 outcome.

	16 mg QD (N = 69)	Cohort 2 Pre-treated (N=90)	Best % tumor size char
Confirmed Best Overall			2) -
Response, n (%)			10-
CR	0	0	
PR	21 (30.4)	27.8%	-10-
SD	28 (40.6)	42.2%	
PD	7 (10.1)	14.4%	
NE	13 (18.8)	15.6%	-50 -
ORR, % (95% CI)	30.4 (19.9, 42.7)	27.8 (18.9, 38.2)	-60 -
DCR, % (95% CI)	71.0 (58.8, 81.3)	70 (59.4, 79.2)	.70 -
Median DoR, months (95% CI)	5.5 (4.9, 8.4)	5.1 (4.2, 5.5)	.80 Best Overall Response Partial Response Subit Discose
Median PFS, months (95% CI)	5.6 (3.9, 7.2)	5.5 (3.9, 5.8)	-00 = Progressite Disease



Drug exposure and side effects

- Median dose intensity 74%
- Rash, diarrhea, stomatitis, and paronychia are common

	16 mg QD (N = 69)
Duration of Treatment (Days), median (min, max)	114 (1, 972)
Relative Dose Intensity, median (min,	74 (21, 100)
max) Patients with Dose Interruption, n (%)	57 (83)
Days to First Dose Interruption, IT (%)	. ,
median (min, max)	18 (3, 174)
Patients with Dose Reduction, n (%)	50 (72)
Days to First Dose Reduction, median (min, max)	36 (9, 204)

- Poziotinib demonstrated clinically meaningful efficacy (ORR 30%) in patients who received and progressed on prior two or more lines of therapy
- The responses were observed regardless of types and sequence of treatment, including in patients who received prior anti-HER2 antibody or ADC therapies.

Xiuning Le, et al.




• MET Exon 14 mutation

- OA21.03: A phase 3b study of 1L savolitinib in patients with locally advanced or metastatic NSCLC harboring MET Exon 14 mutation
- OA21.04: Amivantamab in patients with advanced NSCLC and MET Exon 14 skipping mutation: results from the CHRYSALIS study
- OA21.05: Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET amplification following 1L Osimertinib: INSIGHT 2 primary analysis


OA21.03: A phase 3b study of 1L savolitinib in patients with locally advanced or metastatic NSCLC harboring MET Exon 14 mutation

Study design – 1L patients (treatment naive)



Efficacy (IRC assessment)

	FAC	тоге
	FAS	TRES
	N=87, n (%)	N=84, n (%)
BOR		
PR	5 <u>1 (58.6)</u>	51 (60.7)
SD	29 (33.3)	29 (34.5)
PD	5 (5.7)	4 (4.8)
NE*	2 (2.3)	-
ORR	51 (58.6)	51 (60.7)
Exact 95%CI	(47.6, 69.1)	(49.5, 71.2)
DCR	80 (92.0)	80 (95.2)
Exact 95%CI	(84.1, 96.7)	(88.3, 98.7)
mDoR (mo) (95%Cl)	NR (9.7, NR)	-
mTTR (mo) (95%Cl)	1.4 (1.4, 1.5)	-



Iniciativa científica de:

Ge

ung cance

research


ORR 58.6% by IRC in FAS (60.7% in TRES), indicating a better response in 1L patients

*Reasons for NE: all post-baseline assessments have overall response NE/No post-baseline assessments


BOR: best overall response; mDCR: median disease control rate; mDoR: median duration of response; FAS: Full Analysis Set; IRC: independent review committee; mPFS: median progression free survival; NE: not evaluable; NR: not reached; ORR: objective response rate; PD: disease progression; PR: partial response; SD: stable disease; TTR: time to response

Shun Lu, et al.


OA21.03: A phase 3b study of 1L savolitinib in patients with locally advanced or metastatic NSCLC harboring MET Exon 14 mutation



All types of METex14 could benefit from Savolitinib



(95%CI)
(54.8, 83.2)
(33.8, 66.2)
(1.3, 98.7)
(35.3, 74.5)
(48.7, 75.7)
(2.5, 100.0)
(18.4, 90.1)
(48.6, 71.6)
(2.5, 100.0)



Iniciativa científica de:

Ge


lung cance research

Safety				
Overall Safety	N=87, n (%)	Treatment	related TEAE	
Any TEAE	86 (98.9)	рт	N=87,	
CTCAE grade ≥3 TEAE	70 (80.5)	Oedema peripheral	Total (≥20%) 52 (59.8)	Grade ≥3 6 (6.9)
Treatment related TEAE (TRAE)	85 (97.7)	Aspartate aminotransferase increased	40 (46.0)	12 (13.8)
CTCAE grade ≥3 TRAE	58 (66.7)	Alanine aminotransferase increased	36 (41.4)	14 (16.1)
Serious TEAE (TESAE)	44 (50.6)	Hepatic function abnormal*	30 (34.5)	19 (21.8)
Treatment related TESAE	27 (31.0)	Hypoalbuminaemia	30 (34.5)	0
TRAE leading to dose interruption	27 (31.0)	Nausea Platelet count decreased	29 (33.3) 20 (23.0)	0 2 (2.3)
TRAE leading to dose reduction	63 (72.4)	Blood creatinine increased	20 (23.0)	0
TRAE leading to drug discontinuation	7 (8.0)	White blood cell count decreased	19 (21.8)	2 (2.3)
TRAE leading to death	1 (1.1)	Gamma-glutamyltransferase increased	18 (20.7)	5 (5.7)
AESI	82 (94.3)	Neutrophil count decreased	18 (20.7)	4 (4.6)
Treatment related AESI	81 (93.1)	Blood bilirubin increased Rash	18 (20.7) 18 (20.7)	2 (2.3) 1 (1.1)
Treatment related AESI	81 (93.1)	Rash	18 (20.7)	1 (1.1)

*Hepatic function abnormal included "elevated transaminase with or without bilirubin/ALP increased". AESI: adverse event of special interest; ALP: alkaline phosphatase; CTCAE: Common Terminology Criteria for Adverse Events; PT: Preferred Term; TEAE: treatment-emergent adverse event.

Shun Lu, et al.

OA21.04: Amivantamab in patients with advanced NSCLC and MET Exon 14 skipping mutation: results from the CHRYSALIS study



Iniciativa científica de:

OA21.04: Amivantamab in patients with advanced NSCLC and MET Exon 14 skipping mutation: results from the CHRYSALIS study



	Median follow-up: 10.0 months (n = 97)		
AEs (≥20%) by preferred term, n (%)	Total	Grade ≥3	- 6
Associated with EGFR inhibition			
Paronychia	47 (48.5)	0	
Dermatitis acneiform	40 (41.2)	1 (1.0)	
Rash	37 (38.1)	1 (1.0)	
Stomatitis	27 (27.8)	0	
Pruritus	20 (20.6)	0	
Associated with MET inhibition			
Hypoalbuminemia	37 (38.1)	2 (2.1)	- [
Peripheral edema	36 (37.1)	4 (4.1)	
Other			
Infusion-related reaction	70 (72.2)	4 (4.1)	
Fatigue	28 (28.9)	2 (2.1)	
Dyspnea	22 (22.7)	5 (5.2)	
Hypokalemia	22 (22.7)	3 (3.1)	
Nausea	21 (21.6)	0	
Decreased appetite	21 (21.6)	0	
Alanine aminotransferase increased	20 (20.6)	2 (2.1)	
AEs of special interest by grouped term, n (%)			
Rash ^a	76 (78.4)	3 (3.1)	
Venous thromboembolism ^b	8 (8.2)	2 (2.1)	
Interstitial lung disease ^c	4 (4.1)	1 (1.0)	

iollow-up	o: 10.0 months	



Key takeaway & next steps


- Amivantamab demonstrated meaningful antitumor activity in patients with METex14 advanced NSCLC
 - Treatment-naïve: ORR = 50%
 - No prior MET therapies: ORR = 46%
 - Prior MET therapies: ORR = 21%
- Amivantamab provided durable clinical benefit (median DOR, 11.2 months), with 38% of patients who responded ongoing; the longest response is 29 months to date
- Safety profile was consistent with prior reports¹
- · No new safety signals were observed
- Amivantamab is a bispecific EGFR-MET antibody with immune cell-directing activity and the ability to target METex14 NSCLC in treatment-naïve patients and those with acquired resistance to prior MET therapies due to a unique mode of action
- METalmark (ClinicalTrials.gov Identifier: NCT05488314) is evaluating amivantamab plus capmatinib in patients with METex14 or MET amplification



OA21.05: Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET amplification following 1L Osimertinib: INSIGHT 2 primary analysis

INSIGHT 2: an Open-label, Two-arm Phase II Study¹

- METamp is a common driver of secondary resistance in patients with EGFRm NSCLC following treatment with 1L osimertinib,^{2,3} that may be responsive to MET inhibition
- TBx FISH is the gold standard for METamp detection, with rates of ~50% compared with ~15% by LBx NGS testing^{4,5}



- The trial aims for an ORR in the range of ~50% with a lower limit of the corresponding exact 2-sided 95% CI (according to Clopper–Pearson) to exceed an ORR of 35%
- Subgroup analysis of Asian patients[†] was preplanned
- Data cut-off: March 28, 2023
- Efficacy population has ≥9 months follow-up

We now report the primary analysis




Iniciativa científica de:

Ge

lung cance research

Tae Min Kim, et al.

OA21.05: Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET amplification following 1L Osimertinib: INSIGHT 2 primary analysis



Iniciativa científica de:

 In the primary analysis (TBx FISH), ORR was 50.0% (95% CI 39.7, 60.3), mDOR was 8.5 months (95% CI 6.1, ne), mPFS was 5.6 months (95% CI 4.2, 8.1), and mOS was 17.8 months (95% CI 11.1, ne)

- In Asian patients, ORR was 59.6% (95% CI 45.1, 73.0), mDOR was 7.3 months (95% CI 4.7, ne), mPFS was 6.9 months (95% CI 5.4, 8.4) and mOS was 19.8 months (95% CI 13.6, ne)
- Efficacy outcomes were meaningful in patients with LBx NGS METamp (ORR 54.8%; 95% CI 36.0, 72.7)
- Better outcomes were observed when there were no co-occurring mechanisms of osimertinib resistance
- Tepotinib + osimertinib demonstrated a manageable safety profile, while maintaining HRQoL

Tepotinib + osimertinib provides a potential chemotherapy-sparing oral targeted treatment option for patients with *EGFR*m NSCLC with *MET*amp after progression on 1L osimertinib, who have a high unmet need

Tae Min Kim, et al.





MUCHAS GRACIAS

